SAMe in Post-Concussive Sequelae in The Military with Traumatic Brain Injury (TBI): narrative review

SAMe-Military-TBI

SAMe may help with depression, pain, fatigue, and cognition in the context of metabolic and pathophysiological changes seen in patients who have sustained a mild Traumatic Brain Injury (mTBI), said a newly published study.

The newly published narrative review (Schieffler DA, Matta SE. Mil Med. 2021) examined the preclinical and clinical literature of SAMe’s metabolism and alterations seen in major depressive disorders (MDD), pain disorders, fatigue, cognition and memory, dementia, and other disorders to highlight the potential benefit of SAMe in post-concussive sequelae in mild Traumatic Brain Injury (mTBI).

Combined with a favorable side effect profile, as well as being an over-the-counter supplement that is recognized as generally safe, SAMe may have better acceptance with active duty service members compared with psychotropic medications.

Given its role in cognition and memory seen in preclinical and clinical studies of cognition, along with epigenetic factors associated with DNA methylation status, there is a potential that SAMe may be beneficial in treating cognitive complaints seen in TBI and may decrease the risk of development of dementia.
Although the focus of the article published was on military TBI, the usefulness of SAMe would extend to both civilian and military populations.

What about Traumatic Brain Injury (TBI)

Emergent research has suggested that exposure to repetitive artillery rounds, which may total into thousands, even without clear head injury or alteration of consciousness, may be a risk factor for the development of TBI.

Since the year 2000, over 413,000 service members have sustained what is now considered the signature wound of current wars, with the majority of those sustaining traumatic brain injury (TBI) that is considered mild (83–86%).

HOW SAMe MAY HELP

Numerous studies reviewed the role SAMe plays in cellular energetic imbalances, amino acid alterations, and oxidative stress, which may implicate the connection between SAMe and concussion.

The potential benefit of SAMe in patients with mTBI may highlight how SAMe might mitigate the consequences and impact of increased energy demands of the injured brain.

Lorena Carboni, Product Manager of the branded Adonat® Premium SAMe of Gnosis by Lesaffre says: “The research on SAMe does not stop, highlighting and coming to light more and more on the implications of its metabolism alterations on our brain health and on our brain’s ability to counteract the negative stimuli during life. How described by the Authors, this narrative review serves as the rationale for future open-label and double-blind placebo-controlled trials in military mTBI and SAMe”.

Adonat® Premium SAMe is the leading brand in the market. With more than 30 years of expertise and 10 patents, Adonat® combines state-of-the-art industrial manufacturing, relentless innovation, and esteemed research to achieve proprietary stabilized salts and innovative forms of oral dosage. Discover more.

Share on linkedin
Share on facebook
Share on twitter

DISCOVER ALL OUR LATEST NEWS